Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Schering-Plough Licenses Intranasal Pleconaril For Common Cold

This article was originally published in The Pink Sheet Daily

Executive Summary

The product formulation from ViroPharma is in Phase II. The oral form of the drug, Sanofi's Picovir, received a "not approvable" letter in 2002 from FDA.

You may also be interested in...

Schering-Plough Will Eye Primary Care Acquisitions To Complement Vytorin, Zetia

CEO Hassan vows not to repeat mistakes of Schering's past by relying on the cholesterol agents to carry the business for the long-term. Bayer's oral Factor Xa inhibitor is a potential acquisition candidate, depending on how the antithrombotic fares in Phase III.

Lupus Guidance Suggests Broad Use Of Health-Related Quality Of Life Endpoint

FDA’s draft guidance on systemic lupus erythematosus drug development lists four possible claims that the agency “may be willing to approve”: reduction in disease activity; organ-specific lupus treatment; complete clinical response/remission; and reduction in flares.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts